RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced topline results from two pivotal Phase 3 trials of the investigational, ...
Despite these constraints, the investigators concluded that the results reinforce current perinatal HIV treatment ...
Gilead Sciences, Inc. GILD announced that its investigational single-tablet regimen (STR) of bictegravir and lenacapavir for HIV-1 Treatment met the primary endpoint in the late-stage ARTISTRY-1 study ...
New guidelines update ART choices, endorse long-acting injectables, refine infant feeding advice, and prioritise shorter TB ...
– The Novel HIV Therapy has the Potential to Expand Options for Virologically Suppressed Adults Treated with Complex ART Regimens – – Phase 3 Results from ARTISTRY-1 and 2 Trials will Form the Basis ...
Doravirine/islatravir would be the first FDA-approved two-drug regimen without an integrase inhibitor that demonstrated non-inferior efficacy and a generally comparable safety profile to the ...
A Q&A With Kassem Bourgi, MD. BOURGI: Each year, perhaps 10% to 15% of virologically suppressed patients on a stable regimen explore treatment switching. Most patient-initiated requests are motivated ...
Key goals of EHE include, from 2017 to the end of 2025, reducing new HIV infections and diagnoses by 75%, increasing viral suppression among PWH to 95%, and increasing good or better self-rated health ...
Adolescents with Human Immunodeficiency Virus (HIV) in Botswana, South Africa, Thailand, Uganda and the United States who received the injectable intramuscular antiviral medications cabotegravir and ...
– Positive Phase 3 Results from Both ARTISTRY-2 and ARTISTRY-1 Trials will Form the Basis of Regulatory Submissions – Gilead Sciences, Inc. (Nasdaq: GILD) today announced positive topline results from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results